Daptomycin
Treatment for Endocarditis
Typical Dosage: 6-10 mg/kg IV once daily
Effectiveness
84%
Safety Score
65%
Clinical Trials
15
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
6-10 mg/kg IV once daily
Time to Effect
4-8 days
Treatment Duration
4-6 weeks IV
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$130,000
Side Effect Mgmt:$4,000
Total Annual:$144,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$200,000
Cost per Remission
$232,258
Comparison vs Vancomycin
Cost Difference
+$14,250/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Daptomycin Outcomes
for Endocarditis
Efficacy Outcomes
Overall Effectiveness
+84%
Response Rate
+72%
Remission Rate
+62%
Common Side Effects
Muscle pain/weakness (CPK elevation, rhabdomyolysis)
+7%
GI upset
+7%
Rash
+3%
Eosinophilic pneumonia
+0.5%
Sources:
Active Clinical Trials
2 active trials recruiting for Daptomycin in Endocarditis
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
NCT06637332RECRUITINGPHASE4
300 participants
INTERVENTIONAL
Concord, Australia +12 more
Started: Nov 14, 2024
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
NCT06423898RECRUITINGPHASE4
284 participants
INTERVENTIONAL
Alava, Spain +17 more
Started: Oct 9, 2024
Completed Clinical Trials
5 completed trials for Daptomycin in Endocarditis
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
NCT00093067COMPLETEDPHASE3
INTERVENTIONAL
Started: Mar 1, 2002
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
NCT02142075COMPLETEDPHASE3
INTERVENTIONAL
Angers, France +3 more
Started: Mar 1, 2014
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
NCT03138733COMPLETEDPHASE3
390 participants
INTERVENTIONAL
Chula Vista, United States +59 more
Started: Aug 26, 2018
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
NCT00770341COMPLETEDPHASE3
122 participants
INTERVENTIONAL
Started: Sep 1, 2008
Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients
NCT03961503COMPLETED
72 participants
OBSERVATIONAL
Montpellier, France
Started: Jan 1, 2016